Identifying Biomarkers from Transcriptomic Signatures in Renal Allograft Biopsies Using Deceased and Living Donors

Bin Yang1,2,3*, Nicolas Sylvius4†, Jinli Luo5, Cheng Yang6,7, Zhanyun Da8, Charlotte Crotty1,2 and Michael L. Nicholson1,2,9

1 Department of Cardiovascular Sciences, University of Leicester, Leicester, United Kingdom, 2 Research and Innovation, University Hospitals of Leicester, Leicester, United Kingdom, 3 Nantong-Leicester Joint Institute of Kidney Science, Department of Nephrology, Affiliated Hospital of Nantong University, Nantong, China, 4 Genomics Core Facility, University of Leicester, Leicester, United Kingdom, 5 Bioinformatics and Biostatistics Support Hub Leicester, University of Leicester, Leicester, United Kingdom, 6 Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, China, 7 Shanghai Key Laboratory of Organ Transplantation, Shanghai, China, 8 Department of Rheumatology and Immunology, Affiliated Hospital of Nantong University, Nantong, China, 9 Department of Surgery, Addenbrooke’s Hospital, University of Cambridge, Cambridge, United Kingdom

The survival of transplant kidneys using deceased donors (DD) is inferior to living donors (LD). In this study, we conducted a whole-transcriptome expression analysis of 24 human kidney biopsies paired at 30 minutes and 3 months post-transplantation using DD and LD. The transcriptome profile was found significantly different between two time points regardless of donor types. There were 446 differentially expressed genes (DEGs) between DD and LD at 30 minutes and 146 DEGs at 3 months, with 25 genes common to both time points. These DEGs reflected donor injury and acute immune responses associated with inflammation and cell death as early as at 30 minutes, which could be a precious window of potential intervention. DEGs at 3 months mainly represented the changes of adaptive immunity, immunosuppressive treatment, remodeling or fibrosis via different networks and signaling pathways. The expression levels of 20 highly DEGs involved in kidney diseases and 10 genes dysregulated at 30 minutes were found correlated with renal function and histology at 12 months, suggesting they could be potential biomarkers. These genes were further validated by quantitative polymerase chain reaction (qPCR) in 24 samples analysed by microarray, as well as in a validation cohort of 33 time point unpaired allograft biopsies. This analysis revealed that SERPINA3, SLPI and CBF were up-regulated at 30 minutes in DD compared to LD, while FTCD and TASPN7 were up-regulated at both time points. At 3 months, SERPINA3 was up-regulated in LD, but down-regulated in DD, with increased VCAN and TIMP1, and decreased FOS, in both donors. Taken together, divergent transcriptomic signatures between DD and LD, and changed by the time post-transplantation, might contribute to different allograft survival of two type kidney donors. Some DEGs including FTCD and TASPN7 could be novel biomarkers not only for timely diagnosis, but also for early precise genetic intervention at donor preservation, implantation and post-transplantation, in particular to effectively improve the quality and survival of DD.

Keywords: biomarkers, differentially expressed genes, fibrosis, immunity, inflammation, transplant kidney injury
INTRODUCTION

Kidney transplantation is a life-change treatment for end-stage renal failure patients. It has been reported that 1-year allograft survival increased to around 90% in deceased donors (DD) and 95% in living donors (LD), but 10-year survival fell to 51% and 68% respectively (1, 2). Immunological and non-immunological factors affect chronic allograft injury (CAI) and allograft survival via different mechanistic signaling pathways (3, 4), which need to be explored. Serum creatinine (SCr) or estimated glomerular filtration rate and histopathological score have been widely used, but clinical limitations also appeared in predicting early CAI (5). Virtually no conventional methods or available biomarkers well fit clinical requirements in timely diagnosis and personalized therapy (6).

High throughput genomic technologies, such as microarray, enable investigating hundreds of thousands of genes in one sample at one time, and identifying differentially expressed genes (DEGs) involved in allograft/recipient survival. The microarray analysis has been used to disclose the mechanism of CAI (7), delayed graft function (DGF) (8), rejection (9) and the nephrotoxicity of calcineurin inhibitors (10). A meta-analysis using 150 microarray samples from ischemia-reperfusion (IR) kidneys identified DEGs, corrected the bias in models and species. 26 DEGs including LCN2, CCL2, HMOX1, ICAM1 and TIMP1 were associated with kidney transplantation injury (11). The enrichment of hypoxia and complement-and-coagulation pathways were found in DD kidneys, which might be targeted in donors to improve allograft survival (12). An additional multicenter prospective study reported that 13 genes from 159 renal biopsies at 3 months post-transplantation could discriminate allografts at high or low risk of CAI before irreversible histological damage occurred at 12 months (13). Candidate genes and/or their proteins such as HAVCR1 (KIM-1) and LCN2 (NGAL) in body fluids were also associated with kidney injury (14). The ultimate goal of these studies is to identify and validate DEGs as potential biomarkers to predict and diagnose CAI and improve post-transplantation care.

In this study, genomic analyses were performed in surveillance renal biopsies at 3 months post-transplantation, as well as in paired biopsies obtained at 30 minutes, using DD and LD, for two purposes. Purpose 1 was to identify DEGs between two types of donors (DD vs LD) or two time points (3 months vs 30 minutes) in the first cohort (discovery cohort) of 24 renal biopsies by microarray analysis. The hypothesis was that the difference between DD and LD in terms of survival might be ascribed to the panel of DEGs and maladjusted signaling pathways, and changed by time post-transplantation. Purpose 2 was to validate the DEGs previously identified and involved in kidney diseases and explore the correlation between their expression and functional and histological readouts at prolonged time points in 24 microarray samples and in a second cohort (validation cohort) of 33 renal allograft biopsies (unpaired time points) by reverse transcription quantitative polymerase chain reaction (qPCR). The hypothesis was that selected DEGs at the early time point might be potential biomarkers for early diagnosis and specific intervention of CAI to offering effective personalized post-transplantation care.

MATERIALS AND METHODS

Study Design and Sample Collection

In Leicester, United Kingdom, 80-100 patients per year are transplanted with kidneys: comprising 61% LD including living related and unrelated donors; and 39% DD including donation after brain death and donation after cardiac death. This study was approved by the Ethics Committee, the University Hospitals of Leicester (EDGE34225/UHL10587). From November 2008 to October 2010, 24 renal biopsies were collected from LD and DD paired at 30 minutes (a 30-minute biopsy missed replaced with one collected at day 7 of involved patient) and 3 months post-transplantation for microarray analysis, while additional 33 biopsies time point unpaired were also collected for qPCR validation (Figure 1). With the consent of patients, surveillance...
renal biopsy samples were obtained under ultrasound guidance. Routine biopsy samples were fixed in 10% neutral buffered formalin for histopathological diagnosis, while an additional core of renal tissue was snap-frozen in liquid nitrogen until further research analysis.

**Total RNA Extraction**

Total RNAs were extracted from renal biopsies using an RNeasy® Plus Mini Kit (Qiagen, West Sussex, UK) with gDNAs eliminated columns. Briefly, 10-15 mg tissues were homogenized in 350 µl of RLT Plus buffer containing guanidine thiocyanate, 1% 2-mercaptoethanol, garnet matrix and a ceramic sphere using a FastPrep®-24 homogenizer (MP Biomedicals, Cambridge, UK). Total RNA integrity and quantity were assessed by Bioanalyzer 2100 (Agilent Technologies, Cheshire, UK). Samples with RNA integrity number exceeding 6.5 were qualified for downstream processing (7, 15).

**Microarray Analysis**

Whole-transcriptome profiling was performed using Illumina HumanHT-12 v4 Expression BeadChips (Illumina, Essex, UK), which interrogate 47,231 transcripts targeting 28,688 well-established annotated genes. Raw microarray data were normalized by quantile normalization using the control panel well-established annotated genes. Raw microarray data were normalized using the geometric mean of UBC, PGK1 and HPRT1, which were identified as stable housekeeping genes from microarray data. To identify potential biomarkers, 20 DEGs selected from microarray analysis, P <0.05, fold change (FC) > 1.5, and involved in renal injury, plus 2 previously interested genes CASP1 and CASP3, were further validated by qPCR in 24 microarray samples and 33 biopsies (Supplemental Table 1). FC > 1.5 was chosen after balancing a number of DEGs between compared groups that could best describe the nature of available data, and disclose their association with biological events referring previous publications, as well as further qPCR validation (7, 16).

**Identifying Networks, Pathways, and Biological Functions**

The Ingenuity Pathway Analysis Software v4.0 (Ingenuity® Systems, Redwood City, CA) was used to map each DEG to its corresponding gene object in the Ingenuity Pathways Knowledge Base (17). P-values were calculated using a Right-Tailed Fisher’s Exact Test, which reflected the likelihood and association between a set of DEGs in the input dataset and a given

---

**TABLE 1** | 20 highly DEGs selected from microarray analysis for qPCR validation.

| Name       | Forward sequence | Reverse sequence |
|------------|------------------|-----------------|
| 1          | SERPINA3         | CTGACCTGCTGACGAGGATTTA | TGCAGAAAAGAGGGTGATTT |
| 2          | SLPI             | AATTCCTGATCCCTGTTGAC | AAAAGACCTGACGACCAAGGA |
| 3          | VCAN             | CAAGCTGATGGCTCAGAA | CAAAGAGATGACTGCTCAA |
| 4          | TMP1             | CTCTGCGATGGCTGTTTGG | AGAAGGGCCTGCTGCGGGT |
| 5          | GST1             | TGCTGCGATGACTTGGGAAG | GCCGCTCAATAAACGGTGG |
| 6          | CFB              | AAGCTGCTGAGGAGAAGGG | TCCACACTTCCAGGATG |
| 7          | FGA              | AGCGGATATGAGGAAGAAC | AAAAGACCATGCTCCCAGAC |
| 8          | FOS              | GAGAAGCTTCTGATGCTGTTTGA | AATTCCTAAATGGAACCATAGTATA |
| 9          | CCND1            | CCTGCTCCTACAGGCTCTGCA | CAGAGGGTGGCATGCTGG |
| 10         | DUSP1            | GTGATGAGAGGCTCTGAC | GGTTTCCTAGGAGAGAACA |
| 11         | CX3CL1           | TGGGAGCTGCTGCCTGGTG | CTGGTGGCTGCTCCAG |
| 12         | VHL              | AGTGGAGTCCTGCTCTGGAAG | TGGAGATGGCTGCTGG |
| 13         | CD14             | GCAGGGGTTACGGGCTCTG | TCAGGAGATGGCTGCTGG |
| 14         | ACTRT1           | CGAGGGGTTACGGGCTCTG | GCAGGAGATGGCTGCTG |
| 15         | ARRD4            | TCCGAGGCTGCTGCTCGGTG | GGTTGTCAGGGGCTGCTG |
| 16         | TMEM149          | GGAGGCTGCTGCTGCTGCTG | TGGGATGGCTGCTGCTG |
| 17         | DBI              | TGAGGCTGCTGCTGCTGCTG | TGAGGCTGCTGCTGCTG |
| 18         | UNC5CL           | AGCGGGGACTGCTCTGGAAG | TGGAGGCTGCTGCTGCTG |
| 19         | DARC             | CTGGTGGCTGCTCCTGCTC | CTGGTGGCTGCTCCTGCT |
| 20         | SOST             | TGAGGCTGCTGCTCTGCTG | CTGGTGGCTGCTCCTGCT |
| 21         | CASP3            | GAGGCTGCTGCTGCTGCTG | TGGAGGCTGCTGCTGCTG |
| 22         | CASP1            | GCTGGCTGCTGCTGCTGCTG | CTGGTGGCTGCTGCTGCTG |
| 23         | UBC              | ATTTGCGCTGCTGCTGCTGGT | TGAGGCTGCTGCTGCTG |
| 24         | PGK1             | AAAGGAGGCTGCTGCTGCTG | CTGGTGGCTGCTGCTGCTG |
| 25         | HPRT1            | GCCGAGGCTGCTGCTGCTG | ATTTGCGCTGCTGCTGCTG |

2 previously validated genes (CASP3 and CASP1) and 3 uncharged genes (UBC, PGK1 and HPRT1) were also included.
process/pathway/transcription neighborhood is due to random chance. Gene networks were algorithmically generated based on their connectivity and assigned score to identify biological functions and/or diseases.

**Relevant Clinical End-Points**
Clinical data including the age of donors and recipients, warm and cold ischemic time, anastomosis time, DGF and rejection were collected (18). As chosen clinical end-points SCr and Sirius red (SR) staining were also followed up either at 1-7 days, 1, 3, 6, 12 and 24 months, or 30 minutes, and 12 months. SCr staining representing extracellular matrix collagens I and III deposition (19–21), were performed in paraffin sections using 0.1% SR in saturated aqueous picric acid overnight. Slides were rapidly dehydrated by consequent washing in 0.01 N HCl, 70, 80, 90, 100% ethanol and xylene, and then mounted by DPX mountant. The field of entire renal cortex in each biopsy was semi-quantitatively analyzed at 400 magnification using Image Pro Software (Media Cybernetics, Bethesda, USA).

**Statistical Analysis**
Non-parametric Man Whitney-U test was performed using Illumina GenomeStudio Software v2010.3. Unsupervised hierarchical clustering analysis (HCA, Manhattan average distance) and principal component analysis (PCA, autoscale) were performed using Array Track (22). Correlation analyses between the expression level of DEGs and SCr or SR were performed with Microsoft Excel 2007 and SPSS v20 using the Pearson correlation coefficient. Clinical data such as SCr and SR staining score were expressed as means ± SEMs. Significance was assigned to P ≤ 0.05.

**RESULTS**

**Demographics of Patients and Clinical Data**
Warm ischemic time was shorter, but cold ischemic time was longer in DD vs LD for 12 microarray analysis and 33 qPCR validation patients. There were no significant differences in other parameters such as DGF and rejection episodes. The immunosuppression of all patients was consisted of tacrolimus, mycophenolate modetil and prednisolone.

**Gene Expression Analysis**
All confidently detected genes were analyzed by PCA and unsupervised HCA. Distinct separate clusters were revealed at 30 minutes and 3 months regardless of donor types (Figure 2). Interestingly, the DD biopsy collected at day 7 clearly fell into the gene cluster of 3 months.

The transcriptomic profile was then assessed in 5 DD vs 6 LD biopsies at 30 minutes. 1735 probes corresponding to 1517 annotated DEGs (P < 0.05) were identified, with 446 DEGs at FC > 1.5 (Figure 3). With a view to assessing whether different DEGs were restored later, similar analyses were performed in 6 DD vs 6 LD biopsies at 3 months, with 11 biopsies matched to 30 minutes. 1610 probes corresponding to 1444 annotated DEGs (P < 0.05) were identified, with 149 DEGs at FC > 1.5 (Figure 3). The Venn diagram showed 190 commonly DEGs (DD vs LD, P < 0.05) between two time points, which was reduced to 25 DEGs at FC > 1.5, including GSTM1, SOD2, CCND1 and SLPI (Supplemental Table 2).

| TABLE 2 |
| --- |
| **(A)** Demographic and clinical characteristics of 12 patients for microarray analysis. |
| **Recipient** | **LD 30 min & 3 M (n = 6)** | **DD 30 min & 3 M (n = 6)** | **P value** |
| Age at transplant (yr) | 41.5±7.1 | 49.3±4.0 | NS |
| Sex (% male) | 3 (50%) | 4 (67%) | |
| Donor age (yr) | 48.7±5.6 | 51.7±4.7 | NS |
| HLA mismatch | 2.8±0.9 | 2.5±0.4 | NS |
| Warm ischemia time (h) | 0.08±0.01 | 0.00±0.00 | P < 0.001 |
| Cold ischemia time (h) | 3.7±0.5 | 8.8±1.4 | P < 0.01 |
| Anastomasis time (h) | 0.49±0.09 | 0.53±0.09 | NS |
| Delayed graft function | 0/6 (0%) | 2/6 (33%) | NS |
| Rejection episode | 2/6 (33%) | 2/6 (33%) | NS |

| **(B)** Demographic and clinical characteristics of 33 patients for qPCR validation. |
| **Recipient** | **LD 30 min (n = 6)** | **DD 30 min (n = 6)** | **P value** | **LD 3 M (n = 8)** | **DD 3 M (n = 13)** | **P value** |
| Age at transplant (yr) | 39.5±3.2 | 49.7±7.0 | NS | 51.6±2.6 | 47.0±4.7 | NS |
| Sex (% male) | 5 (83%) | 4 (67%) | NS | 7 (89%) | 9 (69%) | NS |
| Donor age (yr) | 45.3±5.6 | 50.7±6.9 | NS | 47.0±5.8 | 50.0±3.6 | NS |
| HLA mismatch | 2±0.8 | 3±1.0 | NS | 2.8±0.5 | 2.7±0.6 | NS |
| Warm ischemia time (h) | 0.08±0.01 | 0.02±0.02 | P < 0.01 | 0.07±0.01 | 0.02 ± 0.02 | P < 0.05 |
| Cold ischemia time (h) | 5.2±1.7 | 12.0±1.2 | P < 0.01 | 5.1±1.3 | 12.5±0.9 | P < 0.001 |
| Anastomasis time (h) | 0.38±0.01 | 0.50±0.03 | P < 0.01 | 0.47±0.05 | 0.52±0.04 | NS |
| Delayed graft function | 1/6 (17%) | 2/6 (33%) | NS | 0/8 (0%) | 2/13 (15%) | NS |
| Rejection episode | 1/6 (17%) | 2/6 (33%) | NS | 0/8 (0%) | 0/13 (0%) | NS |

The data were expressed as means ± SEMs or % of change.
The top 10 up and down-regulated DEGs (DD vs LD and 3 months vs 30 minutes) is presented (Figure 4). DEGs changed by time post-transplantation, with up-regulation of SERPINA3, FGA, SLPI and SOD2 at 30 minutes (27, 8, 6 and 4 fold-difference between DD vs LD respectively, Figure 4A), and 2-3 folds up-regulation of SLPI, GSTM1, GSTM2 and VCAN at 3 months in DD vs LD (Figure 4B). Interestingly, at 3 months, the two types of donors exhibited different DEGs, with up-regulation of COL3A1, MMM9 and VCAN (9, 6 and 6 fold-difference respectively) and 10-fold down-regulation of FGA in DD (Figure 4D). Also, at 30 minutes vs 3 months, SERPINA3 was found up-regulated by 8 folds in LD vs DD, whereas COL1A1 and COL1A2 were found upregulated by 8 to 10 folds, and FOSB, FOS, ATF3, EGR1, DUSP1, JUN and ZFP36 were downregulated by 8 to 74 folds in both donors (Figures 4C, D).

Functional Annotation, Network, and Pathway Analysis

Functional annotation analysis revealed many up-regulated acute phase response genes at 30 minutes (DD vs LD)
FIGURE 4 | The list of DEGs. Top 10 up and down-regulated genes (DD vs LD, P < 0.05, FC > 1.5) at 30 minutes and 3 months were shown (A, B). In addition, top 10 up and down-regulated genes (3 months vs 30 minutes, P < 0.05 and FC > 1.5) in LD and DD (C, D) respectively were also demonstrated.
including AGT, CFB, TIMP1 and TNFSF10, except SERPINA3, SLPI, SOD2, GSTM1 and FGA described above, were found associated with the cell death including kidney cell apoptosis, proximal tubular toxicity and renal tubule injury (Figure 5A). Some of these dysregulated genes including SLPI, TIMP1 and GSTM1 also seen at 3 months are involved in oxidative stress, inflammation, tubular injury and cell proliferation (Table 3). In addition, adaptive immune response genes in DD or LD kidneys (3 months vs 30 minutes) were also revealed, for instance up-regulated CASP1, CCL5, CX3CRI, VWF, TIMP1 and LCN2 apart from COL3A1 and VCAN; and down-regulated AGT, EGF, CDKN1A and PLG apart from FGA, FOS, FOSB and DUSP1 described above, are associated with immune responses, cell death including apoptosis and necrosis, cell proliferation and tissue remodeling (Figure 5B).

The example network of DEGs was illustrated including SLPI, GSTM1, GSTM2, CD14, CD163, VCAN and CCND1 at 3 months (DD vs LD, Figure 6), as well as the signaling pathway of GSTM1/GSTM2/SLPI-JNK-AKT-ERK-NF-kB-VCAN. An additional schematic picture demonstrated signaling pathways of acute phase response DEGs at 30 minutes, such as TNF-a/IL-1-JNK1/2-P38/MAPK-NF-kB/FOXO-SOD2/CFB, IL-6-PI3K/AKT-mTOR/STAT3-FGA/SERPINA3, and RAS-MEK1/2-ERK1/2-NF-IL6-SERPINA1 in the nucleus, cytoplasm and extracellular space including plasma (Figure 7).

**qPCR Validation**

To validate microarray analysis, 25 genes (Table 1) were quantified by qPCR in the discovery cohort of samples analyzed by microarray. Excellent correlations were shown

---

**FIGURE 5** | Functional annotation of DEGs in acute phase response and adaptive immunity by Ingenuity Pathway Analysis. (A, B) P-values were calculated using a Right-Tailed Fisher’s Exact Test to reflect the association between DEGs and a given process.
### TABLE 3 | Significantly dysregulated genes in 33 additional biopsies validated by qPCR among 20 DEGs relevant to renal diseases.

| Genes    | Change | Comparison                          | P value |
|----------|--------|-------------------------------------|---------|
| SERPINA3 | up     | CAD vs LD at 30 minutes             | 0.041*  |
| SERPINA3 | down   | 3 months vs 30 minutes in CAD       | 0.022*  |
| VCAN     | up     | 3 months vs 30 minutes in LD        | 0.028*  |
| VCAN     | up     | 3 months vs 30 minutes in CAD       | 0.081*  |
| TIMP1    | up     | 3 months vs 30 minutes in LD        | 0.031** |
| TIMP1    | up     | 3 months vs 30 minutes in LD        | 0.092*  |
| VHL      | up     | 3 months vs 30 minutes in LD        | 0.052*  |
| CD14     | up     | 3 months vs 30 minutes in LD        | 0.058*  |
| CFB      | up     | 3 months vs 30 minutes in LD        | 0.075*  |
| UNCSCL   | up     | 3 months vs 30 minutes in LD        | 0.079*  |
| CCND1    | down   | CAD vs LD at 30 minutes             | 0.088*  |
| UBC      | down   | 3 months vs 30 minutes in LD        | 0.062*  |
| GSTM1    | down   | 3 months vs 30 minutes in LD        | 0.097** |
| FOS      | down   | 3 months vs 30 minutes in LD        | 0.001** |
| FOS      | down   | 3 months vs 30 minutes in CAD       | 0.002** |

**P < 0.01; *P < 0.05; #0.05 < P < 0.1.

#### FIGURE 6

This schematic figure demonstrated an example of complicated key network links in DEGs between DD and LD at 3 months generated by function annotation using Ingenuity Pathway Analysis, as well as certain signaling pathways, with red or green color highlighted up or down-regulated genes.
between both detection platforms with correlation coefficient $R^2$ range from 0.70 to 0.94 for most DEGs, for example $R^2 = 0.974$, 0.885 and 0.780 for SERPINA3, TIMP1 and CCND1 respectively at 30 minutes, $R^2 = 0.938$, 0.775 and 0.832 for SLPI, VCAN, VHL respectively at 3 months, and $R^2 = 0.748$ for CASP1 at both time points. The most P-values were significant, except a few genes at borderlines or not confidently detected.

These 25 genes were also quantified by qPCR in a validation cohort of 33 additional biopsies to identify potential biomarkers. In DD, up-regulated SERPINA3 and SLPI, and marginally down-regulated CCND1 were shown at 30 minutes (Table 3), with up-regulated TIMP1, down-regulated SERPINA3 and FOS, marginally up-regulated VCAN at 3 months. At 3 months, up-regulated TIMP1 and VCAN, and down-regulated

---

**FIGURE 7** | This schematic picture illustrated an example of acute phase response signaling pathways in the different compartment of cells such as the nucleus, cytoplasm and extra cellular space produced by Ingenuity Pathway Analysis, with red or green color highlighted up or down-regulated genes.
FOS were revealed in LD, with marginally increased SLPI, CD14, CFB, VHL and UNC5CL (Table 3).

Renal Function and Histological Changes

The patients enrolled in microarray-based gene expression analysis were followed up for 24 months, with relatively stable renal function (Figure 8A), no graft loss, although one patient who had received a DD kidney died due to sepsis-cardiac arrest. No significant differences in SCr (obtained from the clinical database of the University Hospitals of Leicester NHS Trust) between two types of donors were shown at any time points, with a consistent better trend in LD (vs DD) at 2-7 days, 1, 6, 12 and 24 months, except pre-transplantation, 1 day and 3 months. Renal fibrosis assessed by SR staining in 24 microarray and additional 33 biopsies, mainly located in tubulointerstitial areas and scattered in glomerular areas, was increased in DD at 3 and 12 months compared with 30 min, without significant difference in LD (Figure 8B).

Correlation Between DEGs and Clinical Outcomes

To assess whether DEGs at 30 minutes or 3 months could be potential biomarkers to predict allograft survival, the correlations between the expression level of these DEGs, SCr and SR staining were analyzed at the same and extended time points. Using the microarray signal intensity of DD and LD at 30 minutes, a list of top 120 genes was identified significantly correlated with SCr and/or SR staining. For instance, SERPINA3 was found negatively correlated with SCr at 1-7 days, and TNFSF10 was found positively correlated with SCr at 1, 3, 6 and 12 months (Figures 9A, B). The expression levels of 10 DEGs (highly expressed and involved in renal physiopathology based on GO terms or previous publications)
GSTM1, COQ2, CCND1, CFB, FTCD, UNC5CL, SERPINA3, RAI14, TSPAN7 and SOD2 were correlated with both SCr and SR staining at 12 months (Supplemental Table 2). Moreover, at 3 months TSPAN7, BTG3 or COQ2 expression was correlated with SCr, while FAU, UMOD, TSPO, IMPDH2, ADSS, RAF1, ARG2, AGTR1 or PDE6D expression was correlated with SR staining. In addition, other DEGs PTPN6, CNNM3, CSTF3, CHURC1, UCRC, COX7B, FXYD5, CD74, MRPL42P5, SENP2, TMEM129, EIF2AK1, FAM165B, C6ORF66 and ATP5J were also found in four patients with a rejection compared to those without. Above 10 DEGs correlated with both SCr and SR staining were further validated by qPCR in the second cohort of 33 biopsies. In DD (vs LD), there were four up-regulated genes FTCD, SERPINA3, TASP7 and CFB (P < 0.05) at 30 minutes, with a trend of increased SOD2 and decreased CCND1, while raised FTCD and TSPAN7 (P < 0.001) were also seen at 3 months, with marginally up-regulated CCND1 and SOD2.

The correlation between the 10 DEGs and SCr or SR at 12 months in the second cohort of 33 biopsies was further analyzed respectively using Pearson correlation coefficient. CFB (R=-0.669, P=0.034) and COQ2 (R=-0.649, P=0.042) at 30 minutes were significantly correlated with SR at 12 months, while UNC5CL (R=0.553, P=0.098) at 30 minutes was marginally correlated with SCr at 12 months. Other genes at 3 months such as

---

**FIGURE 9** | Correlations between microarray analysis detected DEGs and renal function in the first cohort of 24 biopsies. (A) Negative correlations between SERPINA3 and SCr at early time points from day 1 to 7; (B) Positive correlations between TNFSF10 and SCr at later time points from 1, 3, 6 to 12 months.
COQ2 (R=0.482, P=0.059) or SERPINA3 (R=0.405, P=0.095) were also marginally correlated with SCr or SR at 12 months respectively (Figure 10).

In addition, some DEGs such as SERPINA3, SLPI, VCAN, FOS and SOD2 revealed in this study by microarray analysis, validated by qPCR and associated with kidney injury, were also reported by a previous publication (14) (Supplemental Table 3).

**DISCUSSION**

An increasingly severe shortage of kidney donors leads to the expansion of donor pools by including DD for transplantation. However, the survival of transplant kidneys using DD is not as good as LD. In this study, the microarray analysis of renal allograft biopsies showed divergent transcriptomic signatures between LD and DD, which shifted from acute immune responses at 30 minutes to tissue injury/repair and remodeling/fibrosis at 3 months and might contribute to different long-term survival. DEGs might be attributed to initial donor conditions, innate and adaptive immune responses, persistent inflammation associated with immunosuppressants. Some DEGs including SERPINA3, SLPI, CBF, FTCD, TASPN7, VCAN, TIMP1 and FOS might be novel biomarkers to facilitate timely diagnosis and early therapeutic intervention in donor kidney preservation, implantation or post-transplantation, in particular, effectively improve the donor quality and allograft survival of DD.

Clearly different gene clusters revealed in allograft biopsies between two time points regardless of donor types indicates time post-transplantation playing crucial roles. DEGs affected by time...
post-transplantation might mask initial differences of cold or warm ischemic time in donors, as donation trauma and acute immune responses were overwhelming in implantation. The dramatic changes were eased off, which was reflected by 3 times more DEGs at 30 minutes than 3 months.

We then prioritized to analyze how DEGs (DD vs LD) associated with allograft survival. The functional annotation revealed up-regulated acute response genes SERPINA3, FGA and SLPI, together with inflammation and nephrotoxicity associated genes SOD2, GSTM1, VCAN and TIMP1, but down-regulated repair related genes FGA, CCND1 and FOS in DD at 30 minutes. More fibrotic genes COL3A1, TIMP4 and MMP9 were raised in DD, with increased TIMP1, VCAN, COL1A1 and COL1A2 in both donors at 3 months. The dynamic change of these DEGs well reflected donor initial injury and recipient adaptive immunity via different networks and signaling pathways such as TNF-α/IL-1-JNK1/2-P38/MARK-NF-κB/c-FOS-SOD2/CBF and GSTM1/GSTM2/SLPI-JNK-ATF3/ERK-NF-κB-VCAN. These results were consistent with a study using 59 protocol kidney biopsies that showed immune pathway activation, fibrogenic gene expression and cell proliferation-repair-remodeling at 1, 3 and 12 months respectively (7). 40% DEGs and 50% pathways initially activated were persisted to 3 months, while pro-fibrotic genes were expressed before observed microscopic interstitial fibrosis, suggesting that DEGs might be early biomarkers.

FGA protein is crucial in coagulation, inflammation and tissue regeneration. Soluble fibrinogen-like protein 2 (sFGL2) increased in the circulation of allograft rejection patients, contributed to the apoptosis of cultured tubular epithelial cells (TECs), which is detrimental in early injury, but also initiates remodeling (23, 24). Increased sFGL2 in the recovery stage of auto-transplanted porcine kidneys was associated with inflammatory cell apoptosis and decreased inflammation (25). However, reduced FGA in the plasma of FGA<sup>+/−</sup> mice protected IR kidneys against TEC death and inflammation, with increased CCND1 and proliferation (26). Taken together, down-regulated FGA and CCND1 in DD at 3 months might affect allograft recovery.

SOD2 encoding mitochondrial enzyme protects against IR injury and inflammation (27). SOD2 was found decreased in the urine of aged-mice with increased oxidative stress, apoptosis tubulointerstitial fibrosis and proteinuria (28). GSTM1 protects against xenobiotic compounds and toxicity caused by immunosuppressants in renal transplant recipients. Up-regulated GSTM1 was protective to increased oxidative stress in chronic kidney disease (29). However, GSTM1 was also linked to high rejection risks and unfavorable to long-term allograft outcomes (30, 31). In this study, highly expressed SOD2 and GSTM1 in DD at 30 minutes and 3 months might reflect initial donor injury, as well as self-defense.

Strong positive correlations between two detection methods were shown for most detected DEGs, and potential biomarkers were also identified and validated by qPCR. Up-regulated SERPINA3 and SLPI were shown in DD at 30 minutes with SLPI remained high at 3 months, and raised both in LD at 3 months. SERPINA3 is a secreted acute phase protein associated with inflammatory diseases, a potential pharmacological target (32, 33). Elevated serum SERPINA3 in mice increased the transendothelial permeability of retina associated with diabetic retinopathy (34). Urine SERPINA3 was positively correlated with the activity of lupus nephritis, with SERPINA3 located in endothelial cells and TECs (35), and predicted renal inflammation and fibrosis, especially early transition of AKI to CKD (36). SLPI protein, an inhibiting proteolytic enzyme, participates in mucosa anti-microbial defense by mediating the production of anti-inflammatory cytokines, IL-10 and TGF-β (37). Up-regulated SLPI in epithelial cells plays active roles in defending airways upon inflammation (38). SLPI expressed in TECs of healthy renal biopsies and elevated in serum of uremic patients (39) to regulate proteolytic activity in inflammatory sites (40). SLPI in plasma and urine were increased in AKI post-transplantation, aortic aneurysm repair and cardiac surgery (41–43). SERPINA3 and SLPI, therefore, might be ideal biomarkers of kidney injury.

TIMP1 and VCAN were up-regulated in both DD and LD at 3 months, with reduced FOS. TIMP1 associated with renal IR injury (11), together with matrix metalloproteinases (MMPs), plays important roles in the progression of CAI (44). Urinary/solvent TIMP1/MMPs was/were active in acute tubulointerstitial injury/inflammation (45). VCAN, an indicator of AKI post-transplantation and ongoing parenchymal injury, predicts allograft loss (14). FOS, a transcription factor, involves in MAPK signaling pathway (46). FOS protein has been described as stimulating central opioid receptors, activated renal sympathetic nerves and enhanced IR-induced AKI in mice (47). c-FOS and VEGF play synergistic roles in inflammation and angiogenesis in the peritoneal membrane upon inflammation and lead to ultrafiltration failure (48). The selective inhibitor of c-FOS/activator protein-1 (AP-1, a redox-sensitive transcription factor) inhibited proinflammatory cytokines and improved the survival of lipopolysaccharide-induced AKI (49).

Of note, in the top 10 down-regulated gene list, 7 genes FOSB, FOS, ATF3, EGR1, DUSP1, JUN and ZFP36 were down-regulated in both LD and DD at 3 months. All of them are transcription factors, and immediate early genes in the mouse mononuclear phagocyte system, while they co-expressed with cytokines and chemokines indicates disaggregated cells (50). Hydrogen peroxide-induced apoptosis in mesangial cells via JNK/c-FOS/c-JUN/AP-1 pathway (51). ATF3, a rapidly induced transcription factor by IR, strongly represses the transcription of inflammatory cytokines, plays essential roles in anti-apoptosis, anti-migration and anti-inflammation (52). EGR-1 is a urea-inducible early gene transcription factor in renal inner medullary collecting ducts (53). Biological effects of these genes on CAI are worthy to explore.

Finally, the expression level of 10 DEGs at 30 minutes were found positively correlated with both renal function and histology at 12 months and were validated in 33 additional biopsies to identify more biomarkers. Up-regulated SERPINA3, FTCD, TSPAN7 and CBF were confirmed in both DD and LD at 30 minutes. FTCD, a liver-specific enzyme integrating Golgi complex with vimentin filament cytoskeleton, is linked to autoimmune hepatitis and glutamate formiminotransferase
that other DEGs detected by microarray such as HuMig and between DEGs measured before 3 months post-transplantation rejection or loss would be ideal dataset to explore associations either LD or DD kidneys and showed clear allograft dysfunction, samples collected from a large cohort of patients who received rejection. To validate these DEGs as biomarkers, analyzing were revealed in four patients with a rejection compared to without but DEGs such as PTPN6, CNNM3, CSTF3, CHURC1 and UCRC difference in terms of DGF and rejection between LD and DD, with/without DGF and/or rejection. There was no clinical in large clinic cohorts with long-term follow-up, or in subgroups

Nevertheless, there are certain limitations in this study. A small size of 24 biopsies were used for microarray analysis, but DEGs were revealed between DD and LD at as early as 30 minutes after implantation (a precious therapeutic window), and some of these DEGs were persistent at 3 month. In addition, selected DEGs were also further validated by qPCR in the 24 microarray analyzed samples and additional 33 time point unpaired renal biopsies, and were correlated with renal function and renal fibrosis at extended time points up to 24 months. CASP1 and CASP3, intensively investigated in our previous studies, were not on the list of DEGs, but their importance in transplant-related injuries cannot be excluded as FC > 1.5 and P < 0.05 were selected.

The preliminary data from this study need to be cross-validated in large clinic cohorts with long-term follow-up, or in subgroups with/without DGF and/or rejection. There was no clinical difference in terms of DGF and rejection between LD and DD, but DEGs such as PTPN6, CNNM3, CSTF3, CHURC1 and UCRC were revealed in four patients with a rejection compared to without rejection. To validate these DEGs as biomarkers, analyzing samples collected from a large cohort of patients who received either LD or DD kidneys and showed clear allograft dysfunction, rejection or loss would be ideal dataset to explore associations between DEGs measured before 3 months post-transplantation and adverse outcomes or long-term survival. It has been reported that other DEGs detected by microarray such as HuMig and MIP-3β were abundant in patients with acute rejection (64), CD20 was associated with B cell infiltration and acute rejection (9), and KRT15 and HOXB7 at 6 months were linked to chronic rejection at 12 months (Supplemental Table 3) (65).

The microarray analysis used cdNA synthesized based on total RNA extracted from kidney homogenates might average DEGs in different cells/cell types due to their heterogeneity in kidneys (66). Laser captured microdissection and single cell sequence may be solutions. The relations between DEGs, upstream regulating miRNAs, corresponding proteins and downstream biological events were difficult to fully dissect. Current translational human studies require concurrent genomic, proteomic and metabolomic analysis in small tissues (67). The real time central molecular assessment of kidney transplant biopsies based on Molecular Microscope Diagnostic

System classifier algorithms offers a useful new dimension in biopsy interpretation (68), although mining DEGs in bioinformatics data and transferring to clinical applications are still challenging.

Moreover, a great potential of gene therapy using RNAi has been demonstrated in translational medicine. Registered clinical trials of siRNAs (www.ClinicalTrials.gov) rapidly increased, only 15NP targeting p53 has been validated in kidney injury. siRNA target caspase-3 was renoprotective in our previous studies used a serial of biological models including TEGs and mouse IR kidneys (69, 70). In particular, local and systemic administrating serum stabilized caspase-3 siRNA effectively silenced caspase-3, favorably changed serum cytokines, reduced apoptosis and inflammation, and protected cold static or normothermic machine preserved and auto-transplant porcine kidneys (71, 72). Therefore, siRNA therapy is promising in preservation/resuscitation donors and reducing declined rate of DD (73), and in implantation and post-transplantation to effectively prolong allograft survival.

In conclusion, the transcriptional profile of allograft biopsies is different between 30 minutes and 3 months, with more DEGs between DD and LD at 30 minutes reflected donor injury and recipient innate immunity. Consistent DEGs at 3 months mainly represented adaptive immunity, remodeling or fibrosis. Some DEGs such as SERPINA3, SLPI, CBF, FTCD, TSPAN7, VCAN, TIMP1 and FOS might be novel biomarkers for not only timely diagnosis, but also facilitating precise genetic intervention in donor preservation, implantation and the early stage of post-transplantation, monitoring CAI progression and therapeutic responses, and effectively improving the donor quality and allograft survival of DD.

DATA AVAILABILITY STATEMENT

The datasets presented in this study can be found in an online repository of Gene Expression Omnibus (GEO): https://www.ncbi.nlm.nih.gov/geo, and the accession number of the GEO: GSE178689.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by the Ethics Committee, the University Hospitals of Leicester (EDGE34225/UHL10587). The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

BY, NS, and MN conceived and designed the study. BY, NS, CY, ZD, JL, and CC acquired, analyzed, and interpreted the data. BY and NS wrote the paper. BY approved the final submission of the
manuscript. All authors contributed to the article and approved the submitted version.

**FUNDING**

This study was supported the UK-China Fellowship for Excellence, Department for Business Innovation and Skills (2010/2011) and the National Nature Science Foundation of China (81170689, 81570677 and 81873622).

**ACKNOWLEDGMENTS**

This study was supported by the Research and Innovation, University Hospitals of Leicester NHS Trust, UK.

**REFERENCES**

1. Ibrahim M, Vece G, Mehew J, Johnson R, Forsythe J, Klassen D, et al. An International Comparison of Deceased Donor Kidney Utilization: What can the United States and the United Kingdom Learn From Each Other? *Am J Transplant* (2020) 20:1309–22. doi: 10.1111/aat.15719

2. Cecka JM. The UNOS Renal Transplant Registry. *Clin Transplants* (2002), 1–20.

3. Akalin E, O’Connell PJ. Genomics of Chronic Allograft Injury. *Kidney Int Suppl* (2011) 119:S33–7. doi: 10.1038/ki.2010.420

4. Kezic A, Stajic N, Thaiss F. Innate Immune Response in Kidney Ischemia/Reperfusion Injury: Potential Target for Therapy. *J Immunol Res* (2017) 2017:6305439. doi: 10.1155/2017/6305439

5. Yilmaz S, Isik I, Afrouzian M, Monroy M, Sar A, Benediktsson H, et al. Evaluating the Accuracy of Functional Biomarkers for Detecting Histological Changes in Chronic Allograft Nephropathy. *Transplant Int: Off J Eur Soc Organ Transplant* (2007) 20:608–15. doi: 10.1111/j.1397-3190.2007.00494.x

6. Muhlberger I, Perco P, Fechete R, Mayer B, Oberbauer R. Biomarkers in Renal Transplantation Ischemia/Reperfusion Injury. *Transplantation* (2009) 88: S14–9. doi: 10.1097/TP.0b013e3181af65b5

7. Vitalone MJ, O’Connell PJ, Wawamunno M, Fung CL, Chapman JR, Nankivell BJ. Transcriptome Changes of Chronic Tubulointerstitial Damage in Early Kidney Transplantation. *Transplantation* (2010) 89:537–47. doi: 10.1097/TP.0b013e3181ca7389

8. Guerrieri D, Re L, Petroni J, Ambrosi N, Pilotti RE, Chuluyan HE, et al. Gene Expression Profile in Delayed Graft Function: Inflammatory Markers are Associated With Recipient and Donor Risk Factors. *Mediators Inflamm* (2014) 2014:67361. doi: 10.1155/2014/67361

9. Sarwal M, Chua MS, Kambham N, Hsieh SC, Satterwhite T, Masek M, et al. Molecular Heterogeneity in Acute Renal Allograft Rejection Identified by DNA Microarray Profiling. *N Engl J Med* (2003) 349:125–38. doi: 10.1056/NEJMoa035588

10. Vitalone MJ, Ganguly B, Hsieh S, Latek R, Kulbokas EJ, Townsend R, et al. Transcriptional Profiling of Belatacept and Calcineurin Inhibitor Therapy in Renal Allograft Recipients. *Am J Transplant* (2014) 14:1912–21. doi: 10.1111/ajt.12746

11. Grigoryev DN, Cheranova DI, Heruth DP, Huang P, Zhang LQ, Rabb H, et al. Meta-Analysis of Molecular Response of Kidney to Ischemia Reperfusion Injury for the Identification of New Candidate Genes. *BMJ Nephrol* (2013) 14:231. doi: 10.1186/1471-2369-14-231

12. Damman J, Bloks VW, Daha MR, van der Most PJ, Sanjabi B, van der Vlies P, et al. Hypoxia and Complement-and-Coagulation Pathways in the Deceased Organ Donor as the Major Target for Intervention to Improve Renal Allograft Outcome. *Transplantation* (2015) 99:293–300. doi: 10.1097/TP.0000000000000500

13. O’Connell PJ, Zhang W, Menon MC, Yi Z, Schroppel B, Gallon L, et al. Biopsy Transcriptome Expression Profiling to Identify Kidney Transplants at Risk of Chronic Injury: A Multicentre, Prospective Study. *Lancet* (2016) 388:983–93. doi: 10.1016/S0140-6736(16)30826-1

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2021.657860/full#supplementary-material

**Supplementary Table 1** | Details of 20 selected DEGs (P < 0.05, FC > 1.5) relevant to kidney diseases. FC, fold change. Grey color highlighted DEGs either commonly expressed in two time points or correlated with both SCr and SR staining.

**Supplementary Table 2** | 25 DEGs (No.1-25) between DD & LD in common at 30 min and 3 months, and 10 DEGs (No.2, 3, 19 and 26-30) at 30 minutes correlated with both SCr and SR staining for further qPCR detection to identify biomarkers. SCr, serum creatinine; SR, Sirius red staining.

**Supplementary Table 3** | DEGs revealed by microarray analysis and associated with kidney injury or allograft rejection from this study and previous publications. There were some commonly DEGs (underline) between studies.
Following Kidney Transplantation. *Am J Transplant* (2008) 8:1694–701. doi: 10.1111/j.1600-6143.2008.02297.x

63. Le Quintrec M, Zuber J, Moslin B, Kamar N, Jablonski M, Lionet A, et al. Complement Genes Strongly Predict Recurrence and Graft Outcome in Adult Renal Transplant Recipients With Atypical Hemolytic and Uremic Syndrome. *Am J Transplant* (2013) 13:663–75. doi: 10.1111/ajt.12077

64. Akalin E, Hendrix RC, Polavarapu RG, Pearson TC, Neylan JF, Larsen CP, et al. Gene Expression Analysis in Human Renal Allograft Biopsy Samples Using High-Density Oligoarray Technology. *Transplantation* (2001) 72:948–53. doi: 10.1097/00007890-200109150-00034

65. Scherer A, Krause A, Walker JR, Korn A, Niese D, Raulf F. Early Prognosis of the Development of Renal Chronic Allograft Rejection by Gene Expression Profiling of Human Protocol Biopsies. *Transplantation* (2003) 75:1323–30. doi: 10.1097/01.TP.0000068481.98801.10

66. Yuen PS, Jo SK, Holly MK, Hu X, Star RA. Ischemic and Nephrotoxic Acute Renal Failure are Distinguished by Their Broad Transcriptomic Responses. *Physiol Genomics* (2006) 25:375–86. doi: 10.1152/physiolgenomics.00223.2005

67. Berglund SR, Schwietert CW, Jones AA, Stern RL, Lehmann J, Goldberg Z. Optimized Methodology for Sequential Extraction of RNA and Protein From Small Human Skin Biopsies. *J Invest Dermatol* (2007) 127:349–53. doi: 10.1038/sj.jid.5700557

68. Halloran PF, Reeve J, Akalin E, Aubert O, Bohmig GA, Brennan D, et al. Real Time Central Assessment of Kidney Transplant Indication Biopsies by Microarrays: The INTERCOMEX Study. *Am J Transplant* (2017) 17:2851–62. doi: 10.1111/ajt.14329

69. Yang B, Elias JE, Bloxham M, Nicholson ML. Synthetic Small Interfering RNA Down-Regulates Caspase-3 and Affects Apoptosis, IL-1 Beta, and Viability of Porcine Proximal Tubular Cells. *J Cell Biochem* (2011) 112:1337–47. doi: 10.1002/jcb.23050

70. Wu Y, Chen W, Zhang Y, Liu A, Yang C, Wang H, et al. Potent Therapy and Transcriptional Profile of Combined Erythropoietin-Derived Peptide Cyclic Helix B Surface Peptide and Caspase-3 siRNA Against Kidney Ischemia/Reperfusion Injury in Mice. *J Pharmacol Exp Ther* (2020) 375:92–103. doi: 10.1124/jpet.120.000092

71. Yang B, Hosgood SA, Nicholson ML. Naked Small Interfering RNA of Caspase-3 in Preservation Solution and Autologous Blood Perfusate Protects Isolated Ischemic Porcine Kidneys. *Transplantation* (2011) 91:501–7. doi: 10.1097/TP.0b013e318207949F

72. Yang C, Zhao T, Zhao Z, Jia Y, Li L, Zhang Y, et al. Serum-Stabilized Naked Caspase-3 siRNA Protects Autotransplant Kidneys in a Porcine Model. *Mol Ther* (2014) 22:1817–28. doi: 10.1038/mt.2014.111

73. Zwain Z, Patel M, Stover C, Dormer J, Nicholson ML, Hosgood SA, et al. Comparative Analysis of Risk Factors in Declined Kidneys From Donation After Brain Death and Circulatory Death. *Medicina (Kaunas)* (2020) 56:313–25. doi: 10.3390/medicina56060317

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Yang, Sylvius, Luo, Yang, Da, Crotty and Nicholson. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.